

Table S1. Distribution of *BIRC5* (rs8073069) genotypes according to demographic and clinical factors.

Variable		<i>Survivin</i> (rs8073069)			
		CC	CG	GG	<i>p</i>
		<i>n</i> = 11 (10.6%)	<i>n</i> = 48 (46.2%)	<i>n</i> = 45 (43.3%)	
Sex	Male	7 (9%)	33 (42.3%)	38 (48.7%)	0.1424
	Female	4 (15.4%)	15 (57.7%)	7 (26.9%)	
Age [years]	≥ 66.5	3 (5.9%)	24 (47.1%)	24 (47.1%)	0.2959
	< 66.5	8 (15.1%)	24 (45.3%)	21 (39.6%)	
Disease stage	III	4 (10.5%)	16 (42.1%)	18 (47.4%)	0.8004
	IV	7 (10.6%)	32 (48.5%)	27 (40.9%)	
Distant metastases	No	4 (8.7%)	19 (47.8%)	22 (43.5%)	0.5891
	Yes	7 (12.1%)	29 (48.3%)	23 (39.6%)	
Histopathology	AC	4 (9.3%)	21 (48.8%)	18 (41.9%)	0.1213
	SCC	5 (9.3%)	22 (40.7%)	27 (50%)	
	NOS	2 (28.6%)	5 (71.4%)	-	
Performance status (ECOG score)	0	3 (30%)	9 (50%)	6 (20%)	0.5321
	1	4 (6%)	26 (44.8%)	29 (49.2%)	
	2	4 (14.8%)	13 (48.2%)	10 (37%)	
Smoking status	Smoker	9 (9.3%)	46 (47.4%)	42 (43.3%)	0.2465
	Non-smoker	2 (28.6%)	2 (28.6%)	3 (42.9%)	
Body loss [%]	≥ 10%	4 (11.4%)	13 (37.1%)	18 (51.4%)	0.4115
	< 10%	7 (10.1%)	35 (50.7%)	27 (39.1%)	

Occupational exposure	No	10 (11.1%)	43 (47.8%)	37 (41.1%)	0.5268
	Yes	1 (7.1%)	5 (35.7%)	8 (57.1%)	
Family history of any cancer	No	2 (4.2%)	23 (47.9%)	23 (47.9%)	0.1375
	Yes	9 (16.1%)	25 (44.6%)	22 (39.3%)	
Family history of lung cancer	No	6 (7.8%)	38 (49.4%)	33 (42.9%)	0.2414
	Yes	5 (18.5%)	10 (37%)	12 (44.4%)	

Abbreviations: AC, adenocarcinoma; NOS, not otherwise specified; SCC, squamous cell carcinoma; ECOG, Eastern Cooperative Oncology Group.